Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock is trading at $16.94, up 2.36%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TEVA shares have gain 0.41% over the last week, with a monthly amount glided 18.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] stock has seen the most recent analyst activity on May 12, 2025, when JP Morgan upgraded its rating to a Overweight but kept the price target unchanged to $23 for it. Previously, Argus upgraded its rating to Buy on July 10, 2024, and kept the price target unchanged to $20. On March 08, 2024, upgrade upgraded it’s rating to Neutral but maintained its price target of $14 on the stock. Piper Sandler upgraded its rating to a Overweight and increased its price target to $19 on February 12, 2024. Jefferies upgraded its rating to a Buy and raised its price target to $14 on January 23, 2024. Piper Sandler upgraded its rating to Neutral for this stock on January 03, 2024, and upped its price target to $12. In a note dated December 18, 2023, HSBC Securities initiated an Buy rating and provided a target price of $13 on this stock.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock has fluctuated between $12.47 and $22.80 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] shares were valued at $16.94 at the most recent close of the market. An investor can expect a potential return of 65.29% based on the average TEVA price forecast.
Analyzing the TEVA fundamentals
Teva- Pharmaceutical Industries Ltd. ADR [NYSE:TEVA] reported sales of 16.56B for the trailing twelve months, which represents a growth of 0.84%. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.21 and Total Capital is 0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.71.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.52 points at the first support level, and at 16.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.22, and for the 2nd resistance point, it is at 17.50.
Ratios To Look Out For
For context, Teva- Pharmaceutical Industries Ltd. ADR’s Current Ratio is 1.03. In addition, the Quick Ratio stands at 0.74 and the Cash Ratio stands at 0.15. Considering the valuation of this stock, the price to sales ratio is 1.17, the price to book ratio is 3.10.
Transactions by insiders
Recent insider trading involved Sabag Mark, See “Remarks”, that happened on May 08 ’25 when 0.34 million shares were sold. Officer, Sabag Mark completed a deal on May 08 ’25 to buy 0.34 million shares. Meanwhile, Exec. VP, European Commercial Daniell Richard sold 70961.0 shares on Mar 05 ’25.
